Market Overview

Synta Presents Positive One-Year Follow-up Results for GALAXY-1 Trial of Ganetespib in NSCLC at 15th World Conference on Lung Cancer


Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation
of results from the GALAXY-1 trial, a global, randomized, multi-center
study designed to identify the patients with advanced non-small cell
lung adenocarcinoma most likely to benefit from second-line treatment
with the Company's lead drug candidate, the Hsp90 inhibitor ganetespib,
in combination with docetaxel versus docetaxel alone. The results will
be presented Monday, October 28 2013, at 10:30 AM local time during an
oral session at the 15th World Conference on Lung Cancer
(WCLC) in Sydney, Australia.

Ganetespib is a second-generation inhibitor of the chaperone protein
Hsp90, which is critical for the activation and stability of numerous
proteins that drive cancer growth and proliferation. Ganetespib has been

See full press release

Posted-In: News Guidance Contracts Legal Global


Related Articles (SNTA)

View Comments and Join the Discussion!